Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / BeOne Medicines

Clinicaltrial registered21 Oct 2026

BeOne Medicines

21 Oct 2026: Trial registered · A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
21 Oct 2026
Title
A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies
Conditions
Diffuse Large B-Cell Lymphoma, B-cell Malignancies
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07887646
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at BeOne Medicines

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for BeOne Medicines in our registers.

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.